Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

EIF4E Antikörper

EIF4E Reaktivität: Human, Ratte, Maus IHC Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN966057
  • Target Alle EIF4E Antikörper anzeigen
    EIF4E (Eukaryotic Translation Initiation Factor 4E (EIF4E))
    Reaktivität
    • 124
    • 63
    • 51
    • 19
    • 5
    • 5
    • 5
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    Human, Ratte, Maus
    Wirt
    • 106
    • 17
    • 2
    Kaninchen
    Klonalität
    • 99
    • 26
    Polyklonal
    Konjugat
    • 58
    • 9
    • 8
    • 6
    • 6
    • 4
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    Dieser EIF4E Antikörper ist unkonjugiert
    Applikation
    • 97
    • 51
    • 41
    • 27
    • 27
    • 26
    • 16
    • 15
    • 14
    • 13
    • 7
    • 6
    • 2
    • 1
    • 1
    • 1
    Immunohistochemistry (IHC)
    Spezifität
    ElF4E (Ab-209) antibody detects endogenous levels of total elF4E protein.
    Aufreinigung
    The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
    Immunogen
    The antiserum was produced against synthesized non-phosphopeptide derived from human elF4E around the phosphorylation site of serine 209 (S-G-SP-T-T).
    Top Product
    Discover our top product EIF4E Primärantikörper
  • Applikationshinweise
    WB: 1:500~1:1000
    IHC: 1:50~1:100.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    100ug/100ul.
    Buffer
    Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 50% glycerol
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C
  • Gu, Li, Zhao, Fang, Bu, Frazer, Zhao: "tRNASer(CGA) differentially regulates expression of wild-type and codon-modified papillomavirus L1 genes." in: Nucleic acids research, Vol. 32, Issue 15, pp. 4448-61, (2004) (PubMed).

    Li, McDonald, Nassar, De Benedetti: "Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression." in: Annals of surgery, Vol. 227, Issue 5, pp. 756-6l; discussion 761-3, (1998) (PubMed).

    Ohlmann, Rau, Pain, Morley: "The C-terminal domain of eukaryotic protein synthesis initiation factor (eIF) 4G is sufficient to support cap-independent translation in the absence of eIF4E." in: The EMBO journal, Vol. 15, Issue 6, pp. 1371-82, (1996) (PubMed).

  • Target
    EIF4E (Eukaryotic Translation Initiation Factor 4E (EIF4E))
    Abstract
    EIF4E Produkte
    Pathways
    BCR Signaling
Kundenservice